Clinical pharmacy

PrecisePK Pioneers Model-Informed Precision Dosing and Pharmacokinetics Advancements in Argentina with Maza University

Retrieved on: 
Wednesday, December 6, 2023
Clinical pharmacy, Health, Clinical, Acquisition, SAN, Evidence-based practice, Plasma, Risk, Student, Patient, Pharmacology, Medicine, Anticonvulsant, Faculty, Pharmacokinetics, Blood, Health system, Software, Partnership, Huế Central Hospital, Intensive care medicine, Neurology, Education, Knowledge, Central Hospital, Juan Agustín Maza University, Pharmaceutical industry, Nursing, Biochemistry, Pharmacy

Through a strategic collaboration with the reputable Faculty of Pharmacy and Biochemistry, Maza University became the inaugural institution in Argentina to acquire pivotal pharmacokinetics software.

Key Points: 
  • Through a strategic collaboration with the reputable Faculty of Pharmacy and Biochemistry, Maza University became the inaugural institution in Argentina to acquire pivotal pharmacokinetics software.
  • Maza University leverages PrecisePK for Bayesian personalized drug dosing in Argentina, advancing clinical education.
  • "The acquisition of this software is of great relevance for the academic and scientific community since it makes Maza University the first university in Argentina to acquire a Bayesian Model-Informed Precision Dosing software for the training of its students in pharmacokinetics.
  • This strategic alignment between PrecisePK and Maza University symbolizes an unprecedented fusion of academic prowess and real-world application.

CCHIO, a Milestone Event for the Global Cancer Community, Returns to Tianjin in 2023

Retrieved on: 
Wednesday, November 15, 2023
Ministry, Research, Education, CACA, Cancer, Alternative medicine, National Health Commission, Hospital, CJCO, History, Holism, Congress, City, Palliative care, CCO, Clinical pharmacy, Health, Nursing, Chinese, Science

TIANJIN, China, Nov. 15, 2023 /PRNewswire/ -- The 2023 edition of the Chinese Congress of Holistic Integrative Oncology will be held from November 16th to 19th in Tianjin, China. Organized by the China Anti-Cancer Association and co-hosted by Tianjin Medical University Cancer Institute & Hospital, Tianjin Anti-Cancer Association, and the China Institute of Integrative Medicine Development Strategy, the congress aims to strengthen the action and impact of the cancer community. It features over one hundred sessions covering the full spectrum of cancer, from prevention to palliative care, with the attendance of many academicians and top-level experts.

Key Points: 
  • TIANJIN, China, Nov. 15, 2023 /PRNewswire/ -- The 2023 edition of the Chinese Congress of Holistic Integrative Oncology will be held from November 16th to 19th in Tianjin, China.
  • It features over one hundred sessions covering the full spectrum of cancer, from prevention to palliative care, with the attendance of many academicians and top-level experts.
  • Tianjin Medical University Cancer Institute and Hospital (TMUCIH) is the birthplace of Oncology in China.
  • TMUCIH publishes the cancer journal Chinese Journal of Clinical Oncology (CJCO) and its English edition Cancer Biology & Medicine.

Syros Announces Planned CEO Leadership Transition and Strategic Reorganization to Support Long-Term Business Growth and Maturation into a Commercial Biopharmaceutical Company

Retrieved on: 
Monday, October 2, 2023
Biotechnology, Health, Pharmaceutical, Cardiology, Oncology, Workforce, APL, University, Partnership, Arsenic trioxide, International business development, Pharming, Acute promyelocytic leukemia, Personalized medicine, Cancer, Business, CCO, RARA, Acute myeloid leukemia, MDS, AML, Azacitidine, Retirement, Novartis, Patient, CBO, Biology, Bone marrow, Growth, Venetoclax, Pfizer, Clinical pharmacy, Management, Pharmaceutical industry, Capmatinib, Pasireotide, Syros

Also today, Syros announced the retirement as Chief Executive Officer (CEO) of Nancy Simonian, M.D., and the appointment of Conley Chee, Syros’ Chief Commercial Officer (CCO) and Chief Business Officer (CBO), as CEO, effective December 2, 2023.

Key Points: 
  • Also today, Syros announced the retirement as Chief Executive Officer (CEO) of Nancy Simonian, M.D., and the appointment of Conley Chee, Syros’ Chief Commercial Officer (CCO) and Chief Business Officer (CBO), as CEO, effective December 2, 2023.
  • Dr. Simonian will remain a member of the Syros Board of Directors following the transition.
  • This includes streamlining our team and, due to capital constraints, stopping further investment in SY-2101 for the foreseeable future.
  • As we look toward near-term data catalysts from SELECT-MDS-1 and SELECT-AML-1, we are planning for our next phase of growth.

Portugal's Health Systems Achieve Breakthrough with PrecisePK's Bayesian Precision Dosing, Pioneering Personalized Care

Retrieved on: 
Wednesday, August 30, 2023
Partnership, Obesity, Antimicrobial stewardship, Methicillin-resistant Staphylococcus aureus, Amputation, LSHS, Unidade Habitacional de Santo António, MRSA, Pharmacokinetics, Infection, Evidence-based practice, Dialysis, Clinical pharmacy, Pharmacist, Vancomycin, Patient, SAN, AUC, Medicine, Hospital, Health, Fungal infection, TDM, Pharmaceutical industry, Nursing

Such progress marks a pivotal milestone in transforming digital health and personalized care for Portugal's healthcare system.

Key Points: 
  • Such progress marks a pivotal milestone in transforming digital health and personalized care for Portugal's healthcare system.
  • PrecisePK gains trust in Portugal as a key clinical decision support tool for vancomycin dosing in vulnerable patients.
  • PrecisePK's cutting-edge model-based drug dosing solutions have been successfully piloted at Hospital de Cascais, a prominent public site within the Luisadas Saude Health.
  • By leveraging model-informed precision dosing technology, LSHS can now conduct enhanced precision dosing that is data-driven.

Edmonton Unlimited Opens City’s Newest Innovation Destination to Fuel Inclusive Ecosystem

Retrieved on: 
Friday, May 12, 2023
EAP, Culture, Municipal council, Organization, Clinical pharmacy, City, STEM, Dentons, Ecosystem, Jasper Avenue, Unlimited, Oil, Amusement park, Pharmacy

The City-funded organization positions Edmonton as an inclusive global innovation capital, accelerating Edmonton-made solutions to global challenges.

Key Points: 
  • The City-funded organization positions Edmonton as an inclusive global innovation capital, accelerating Edmonton-made solutions to global challenges.
  • “Edmonton Unlimited was created by City Council with a mandate of innovation and ecosystem building.
  • “Edmonton Unlimited creates an inclusive and supportive environment, unlocking unlimited potential and empowering local businesses to redefine what's possible in our city."
  • We thank Edmonton Unlimited for doing this meaningful work, positively impacting our global business opportunities.”
    Edmonton Unlimited is now open to Edmonton’s innovation communities.

Quest Diagnostics Unveils Advanced Transplant Diagnostic Services Featuring Anywhere-Access in the United States

Retrieved on: 
Wednesday, March 22, 2023
Yale New Haven Hospital, Quest Diagnostics, BCPS, Travel, Doctor of Pharmacy, Senior, HIV, APOL1, Apolipoprotein L1, HLA, EMR, Infection, Hepatitis C, Transplant, Clinical pharmacy, Kidney disease, Patient, Collection, Risk, Immune system, NYSE, DGX, Nursing, Dentistry, Medical device, Quest

SECAUCUS, N.J., March 22, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, today unveiled a comprehensive suite of advanced diagnostics and support services designed to broaden access to laboratory tests for transplanting solid organ, human cells and tissue.

Key Points: 
  • The specialized services are available to recipients and living donors across the United States (excluding Alaska and Hawaii), broadening access for candidates for transplant and their donors.
  • The option for at-home specimen collection from one of 5,000 mobile phlebotomists through ExamOne, a Quest Diagnostics company, for both transplant recipients and living donors.
  • Apolipoprotein L1 (APOL1) Renal Risk Variant Genotyping, an advanced genetic test to help evaluate kidney disease risk for donors.
  • "In collaboration with Quest, transplant centers, hospital health systems and other providers can ensure living donors, recipients and care teams can access the advanced and personalized transplant diagnostics they need, even if the center performing the transplant surgery is many miles away.

Viracta Therapeutics Appoints Jane Chung, R.Ph., to its Board of Directors

Retrieved on: 
Thursday, August 11, 2022
Mount Sinai Hospital, HDAC, Multimedia, Effectiveness, AstraZeneca, Valganciclovir, Industry, Sutro Biopharma, Genentech, Senior, Private Securities Litigation Reform Act, Commercial Operating System (COS), SEC, Leadership, Board, Research, Communication, Epstein–Barr virus, Government, Marketing, Patient, General manager, Therapy, COVID-19, Education, SAN, Board of directors, Columbia University, Risk, Saint John's University, Institutional review board, EBV, Clinical pharmacy, Science, University, Nasdaq, Time, NY, Pharmaceutical industry, Psychology, Pharmacy

SAN DIEGO, Aug. 11, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the appointment of Jane Chung, R.Ph., as an independent member to its Board of Directors.

Key Points: 
  • SAN DIEGO, Aug. 11, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the appointment of Jane Chung, R.Ph., as an independent member to its Board of Directors.
  • "Ms. Chung's unique combination of commercial and executive experience in oncology make her an ideal fit for Viracta's Board," said Roger J. Pomerantz, M.D., F.A.C.P., Chairman of the Board of Directors of Viracta.
  • It is my pleasure to welcome her to the Board and I am eager to begin working together."
  • Viracta assumes no obligation and does not intend to update these forward-looking statements, except as required by law or applicable regulation.

International Healthcare Executive, Georgina Rizik, to Lead London’s New Life Sciences Innovation District, SC1

Retrieved on: 
Friday, June 24, 2022
Science, Biotechnology, Research, Pharmaceutical, Finance, Oncology, Health, Professional Services, Patient, Heart, Research, Marketing, Foundation, Industry, Organic, University, Roche, Clinical pharmacy, Life, MP, King's Health Partners, Student, Academic health science centre, Regeneration, Health equity, Innovation, MBA, Investment, Cabinet, Boehringer Ingelheim, Education, Creative, CEO, Novartis, Senior, Workforce, Health, NHS, List of life sciences, NHS foundation trust, SC1, Board, Royal Brompton Hospital, Hospital, King's College London, Royal Street, New Orleans, Imperial College London, Economic development, Management, Healthcare, Creative industries, Medicine, Ipsen, Biotechnology, Biotechnology, Pharmacy, Science

SC1, Londons new Life Sciences Innovation District being developed in south central London, UK, has announced the appointment of a new Executive Director, Georgina Rizik.

Key Points: 
  • SC1, Londons new Life Sciences Innovation District being developed in south central London, UK, has announced the appointment of a new Executive Director, Georgina Rizik.
  • Georgina is a leading international healthcare and biotechnology commercial executive with over 25 years experience across private, public and non-profit organisations.
  • Starting in June, Georgina will lead SC1, which was founded by Kings Health Partners, Guys & St Thomas Foundation, and Lambeth and Southwark councils.
  • It is a privilege and honour to be the leader for SC1, Londons Life Sciences Innovation District.

Pear Therapeutics to Present at 2022 Rx and Illicit Drug Summit

Retrieved on: 
Monday, April 18, 2022
Biotechnology, Health, Pharmaceutical, Technology, Software, Patient, Buprenorphine, CEO, MCPHS University, Language isolate, Suicidal ideation, Drive, Health equity, Population, COVID-19, MBA, Policy by press release, Software, MD, Clinical pharmacy, Pharmacist, OUD, Associate, GMP, Organization, Session, Opioid use disorder, SUD, Smartphone, Therapy, Doctor of Pharmacy, Environment, Insomnia, Reading, Cognitive behavioral therapy, PEAR, Safety, Digital, Substance use disorder, Reset, Population Health Management, Ballroom dance, FDA, Chief Medical Officer (Ireland), Risk, Pear, Medicaid, Pharmaceutical industry, Birth control, Hospital, Mobile phone, Medical device, PDT, Nasdaq

Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will host an educational Vision Session at the Rx and Illicit Drug Summit (Rx Summit), April 18-21 in Atlanta, GA.

Key Points: 
  • Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will host an educational Vision Session at the Rx and Illicit Drug Summit (Rx Summit), April 18-21 in Atlanta, GA.
  • The Rx Summit is the largest annual gathering for global stakeholders to address the opioid and addiction epidemic and share best practices and strategies for prevention, treatment, and recovery.
  • To learn more about the Session, which will take place on Tuesday, April 19 at 8:00 ET in International Ballroom A-D, please visit www.rx-summit.com/agenda .
  • Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs).

CloudMD Announces Cost Optimization and Operational Integration Activities

Retrieved on: 
Thursday, March 31, 2022
Company, Marketing, Eastman Kodak Co. v. Image Technical Services, Inc., Organization, COO, Telehealth, EVP, OTCQX, Growth, Health, Pharmacy, Clinical pharmacy, Digital Solutions, SVP, Corporation, Artificial intelligence, Industry, Technology, Review, Ecosystem, Human resources, GLOBE, Student, Transformation, Strategic planning, Risk management, Pharmaceutical industry, Management, Medicine, Engineering

CloudMDs cost optimization team is dedicated to creating shareholder and client value through the integration of people, process, and technology across the entire organization.

Key Points: 
  • CloudMDs cost optimization team is dedicated to creating shareholder and client value through the integration of people, process, and technology across the entire organization.
  • As part of the cost optimization, CloudMD has made some changes to its organizational structure to streamline the operations and create a more efficient business.
  • CloudMD has also introduced a process to continually review and evaluate its operational integration and additional changes may be implemented as indicated by such process.
  • We are focusing on higher productivity and sustainable cost effectiveness to position us for increased profit and scalability, stated Karen Adams, President of CloudMD.